Introduction
High grade/ grade-3 tumours (T1-HG/G3) with lamina propria invasion form the highest risk category of nonmuscle invasive bladder cancer (NMIBC) for progression to muscle invasive disease and cancer specific mortality [1] . The only treatment modality which can reduce the risk of progression is intravesical Bacillus Calmette Guerin (BCG) immunotherapy and the patient should indeed receive optimal BCG therapy-i.e.BCG induction with a six-week induction course followed by maintenance [2] . In Sri Lanka, T1-HG/G3 patients did not receive intravesical BCG due to non-availability during the study period (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) .
The objective of this study was to evaluate the clinical outcomes of recurrence, progression, recurrence free survival, progression free survival and overall survival in a cohort of patients with T1-HG/G3 detected after transurethral resection of bladder tumour (TURBT) that did not receive intravesical BCG therapy.
Methodology
Patients with primary T1G3 (WHO-1973) T1-HG (ISUP/WHO-2004) NMIBC tumour, formed the retrospective study cohort (prospectively collected data) studied at one of two urology units at the National Hospital of Sri Lanka, Colombo between January-2000 and December-2014. All patients underwent a TURBT and 
Results
A total of 83 patients had pT1-HG tumours during the 15-year study period. The majority were males (n=76; 91.6%). Median age was 67 years (IQR:59-73). Visible (macroscopic) haematuria was the commonest clinical presentation (n=76; 91.6%). Median duration of symptoms was 1 month (range:0.25-24.0).
The majority were papillary tumours (n=58,69.9%), solid tumours were seen in 11 (13.2%) and mixed tumours (presence of papillary and solid components) were seen in 14 (16.9%) patients. Majority were solitary tumours (n=58;69.9%) but 15 (18%) had three or more tumours. None of the patients had concomitant Tis (carcinoma insitu). Muscle in the tissue specimen was seen in 48 (57.8%) patients. Eighteen (21.7%) were lost to follow up after the first surgery. The median duration of the first recurrence was 4.7 months (IQR:2.9-17.1) and progression was 18 months (IQR:5.6-42.2). Sixteen patients progressed to pT2 while two patients to pT3 and one patient to pT4. The summary of follow up and survival characteristics is given in Table 1 .
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Discussion
This study included 83 consecutive patients not receiving intravesical BCG after the initial TURBT. The sample had a male preponderance (91.6%) with a median age of 67 years. The median duration of first recurrence was 4.7 months (IQR:2.9-17.1) and progression was 18 months (IQR:5.6-42.2).
Intravesical BCG immunotherapy after the initial TURBT was the standard of care in the West for pT1-HG/ G3 disease even at the commencement of this study. However due to the non-availability of intravesical BCG in Sri Lanka consequent to the limited health budget during the study period, all patients underwent TURBT followed by cystoscopic bladder surveillance only. A significant number (21.7%) was lost to follow up after the initial TURBT. Even in the recurrence-free patients (26.1% of those followed up) the median follow-up was 15.3 months. This is a reflection of the large catchment population of the institution (over 8 million) and the long distances (over 100-200 km) travelled by patients from home to the hospital. We can assume that most of these patients had not developed recurrent episodes of visible haematuria, a symptom of neglected bladder tumour recurrence, that would compel them to report back to the same urology unit. The median duration of follow-up of the 65 patients (78.3%) eventually studied was 18.3 months.
In the present study, 73.8% developed recurrences and 29.2% progressed to muscle invasive disease. The median follow-up of those who developed recurrences and progression were 22.5 and 20.3 months respectively. The 1, 5 and 10-year recurrence-free survival was 27%, 12.3% and 4.6% respectively and progression-free survival was 60%, 18.5% and 9.2% respectively.
In a study by Peyromaure et al. of 57 T1-G3 urothelial bladder cancer (UBC) patients who received intravesical BCG therapy, the median follow up was 53 months (range: 9-110 months). The recurrence rate and the progression rate were 42.1% and 22.8% respectively [3] . Fifty patients (87.7%) had no residual disease after the first BCG course. Margel et al. documented a series of 78 patients with T1-HG UBC treated by intravesical BCG with a median follow up of 107 months (range:16-238). The recurrence rate was 35% at a median follow-up of 18.5 months and progression was 18% at a median of 31.4 months following treatment [4] . The 2, 5 and 10 year recurrence-free survival rates were 76%, 72% and 62% respectively and progression-free survival rates were 92%, 82% and 80% respectively [4] . A major limitation of the present study, therefore, is the short median follow-up of 18.3 months.
These studies demonstrate a significant reduction in the recurrence rates and lesser progression rates with longer median follow-up. However, the striking comparison between those who receive intravesical BCG and those who do not in regard to their recurrence-free survival and progression-free survival makes intravesical BCG immunotherapy a mandatory component in the treatment of T1-HG UBC.
In a prospective randomised trial, 86 high grade patients with NMIBC were randomly assigned to receive either TURBT (n=43) or TURBT plus intravesical BCG (n=43). BCG was administered weekly for 6 weeks only. The 10-year progression free rate was 61.9% for patients treated with BCG and 37% for TURBT alone group [5] .
Conclusion
High grade pT1 UBC not treated by intravesical BCG after the initial TURBT demonstrate a high rate of recurrence and greater propensity to progression into muscle invasive bladder cancer. At least a six-week BCG induction course alone (without maintenance) is worthy of consideration in the management of patients with pT1-HG UBC in Sri Lanka where the resources are limited.
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